

April 2019, Volume 80, Number 4

## CONTENTS

---

### Continuing Medical Education

- CME 835** Onychomycosis  
Clinical overview and diagnosis  
*Shari R. Lipner, MD, PhD, and Richard K. Scher, MD*
- 851** Answers to CME examination (Identification No. JA0419),  
April 2019 issue of the *Journal of the American Academy of  
Dermatology*
- 852** **CME examination**
- CME 853** Onychomycosis  
Treatment and prevention of recurrence  
*Shari R. Lipner, MD, PhD, and Richard K. Scher, MD*
- 867** Answers to CME examination (Identification No. JB0419),  
April 2019 issue of the *Journal of the American Academy of  
Dermatology*
- 868** **CME examination**
- CME 869** Angioinvasive fungal infections impacting the skin  
Background, epidemiology, and clinical presentation  
*Bridget E. Shields, MD, Misha Rosenbach, MD, Zoe Brown-Joel, BS,  
Anthony P. Berger, MD, Bradley A. Ford, MD, PhD, and  
Karolyn A. Wanat, MD*
- 881** **CME examination**
- 882** Answers to CME examination (Identification No. JC0419),  
April 2019 issue of the *Journal of the American Academy of  
Dermatology*
- CME 883** Angioinvasive fungal infections impacting the skin  
Diagnosis, management, and complications  
*Anthony P. Berger, MD, Bradley A. Ford, MD, PhD, Zoe Brown-Joel, BS,  
Bridget E. Shields, MD, Misha Rosenbach, MD, and  
Karolyn A. Wanat, MD*

	<b>899</b>	<b>CME examination</b>
	<b>900</b>	Answers to CME examination (Identification No. JD0419), April 2019 issue of the <i>Journal of the American Academy of Dermatology</i>
<b>Letter from the Editor</b>	<b>901</b>	Responding to reviewers: Advice to young (and some older) authors <i>Dirk M. Elston, MD</i>
<b>A Clinician's Perspective</b>	<b>902</b>	The hydroxychloroquine—interferon gamma release assay question: TB or not TB? <i>Warren R. Heymann, MD</i>
<b>From the Dermatology Foundation</b>	<b>904</b>	Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: A systematic review and meta-analysis <b>Bottom line: Risk for infection should be incorporated into clinical decision-making of atopic dermatitis patients.</b> <i>Linda Serrano, MD, Kevin R. Patel, BS, and Jonathan I. Silverberg, MD, PhD, MPH</i>
<b>Original Articles</b>	<b>913</b>	Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study <b>Bottom line: Baricitinib is a potential treatment option for AD.</b> <i>Emma Guttman-Yassky, MD, PhD, Jonathan I. Silverberg, MD, PhD, MPH, Osamu Nemoto, MD, PhD, Seth B. Forman, MD, August Wilke, PhD, DABT, Randy Prescilla, MD, Amparo de la Peña, PhD, Fabio P. Nunes, MD, MMSc, Jonathan Janes, MB, BCH, FRCP, Margaret Gamalo, PhD, David Donley, PhD, Jim Paik, PharmD, Amy M. DeLozier, MPH, Brian J. Nickoloff, MD, PhD, and Eric L. Simpson, MD, MCR</i>
	<b>922</b>	Intralesional immunotherapy for the treatment of warts: A network meta-analysis <b>Bottom line: Purified protein derivative vaccine and measles, mumps, and rubella vaccine may be considered as first-line treatments for warts.</b> <i>Samar Salman, MSc, Mohamed Shehata Ahmed, MedSci, Ahmed Mohamed Ibrahim, MBBCh, Omar Mohamed Mattar, MedSci, Hassan El-Shirbiny, MedSci, Sameh Sarsik, MSc, Ahmed M. Afifi, MBBCh, Ruba Marwan Anis, MedSci, Nadim Aiman Yakoub Agha, MedSci, and Abdelrahman Ibrahim Abushouk, MBBCh</i>

- 931** Association between itch and cancer in 16,925 patients with pruritus: Experience at a tertiary care center  
**Bottom line:** Knowledge of this association can guide clinicians in pursuing a malignancy workup for patients with unexplained pruritus.  
*Valerie A. Larson, MS, Olive Tang, BS, Sonja Ständer, MD, Sewon Kang, MD, and Shawn G. Kwatra, MD*
- 938** A population-based registry study on relative survival from melanoma in Germany stratified by tumor thickness for each histologic subtype  
**Bottom line:** Increased 5-year relative survival between the periods 2002–2005 and 2010–2013 is explained by a decrease in tumor thickness. Prevention and awareness should be encouraged, as the prognosis of thick melanoma is still poor.  
*Alicia Brunssen, MA, Lina Jansen, PhD, Nora Eisemann, PhD, Annika Waldmann, PhD, Janick Weberpals, RPh, Klaus Kraywinkel, MD, Andrea Eberle, PhD, Bernd Holleczek, PhD, Sylke Ruth Zeissig, MD, Hermann Brenner, MD, and Alexander Katalinic, MD, for the GEKID Cancer Survival Working Group*
- 947** Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis  
**Bottom line:** Laser-assisted photodynamic therapy is an attractive option for patients with multiple actinic keratoses or field cancerization.  
*Theresa Steeb, MPH, Justin Gabriel Schlager, MD, Christoph Kohl, MSc, Thomas Ruzicka, MD, Markus V. Heppt, MD, MSc, and Carola Berking, MD*
- 957** Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review  
**Bottom line:** Information on fertility effects or teratogenicity risk should guide discussions with male patients who are using these medications and looking to conceive.  
*George A. Zakhem, BS, Catherine C. Motosko, BS, Euphemia W. Mu, MD, and Roger S. Ho, MD, MS, MPH*
- 970** Extremity nevus count is an independent risk factor for basal cell carcinoma and melanoma, but not squamous cell carcinoma  
**Bottom line:** Having any extremity nevi increases risk for basal cell carcinoma and melanoma on all body sites; highest risks are seen in those with 15 or more extremity nevi.  
*Erin X. Wei, MD, Xin Li, ScD, and Hongmei Nan, PhD*
- 979** Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival  
**Bottom line:** Increased utilization of those aspects of these centers that increase patient survival, whether by regionalization of care or dissemination of these practices, may improve patient outcomes.  
*Shayan Cheraghlou, BA, George O. Agogo, PhD, and Michael Girardi, MD*

- 990** Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management  
**Bottom line:** There are key distinctions among the rashes that develop from checkpoint inhibitors with regards to severity and impact on cancer treatment.  
*Emily Coleman, BA, Christine Ko, MD, Feng Dai, PhD, MS, Mary M. Tomayko, MD, PhD, Harriet Kluger, MD, and Jonathan S. Leventhal, MD*
- 998** Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study  
**Bottom line:** Whereas 5-fluorouracil was more effective in reducing risk of keratinocyte carcinoma overall, we found no differences in the short- or long-term risk of site-specific keratinocyte carcinoma.  
*Romain Neugebauer, PhD, Katherine A. Su, MD, Zheng Zhu, MS, Monica Sokil, BA, BS, Mary-Margaret Chren, MD, Gary D. Friedman, MD, MS, and Maryam M. Asgari, MD, MPH*
- 1006** Increased risk for incident thyroid diseases in people with psoriatic disease: A cohort study  
**Bottom line:** Our findings can serve as a guide for thyroid disease risk stratification for patients with psoriatic disease.  
*Shu-Hui Wang, MD, MS, Jui Wang, MPH, Yu-Sheng Lin, MD, Tao-Hsin Tung, PhD, and Ching-Chi Chi, MD, MMS, DPhil, FAAD*
- 1013** Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial  
**Bottom line:** Findings at later time points suggest that future clinical trials may require longer treatment periods to determine a significant treatment effect.  
*Eric L. Simpson, MD, Jane R. Parnes, MD, Dewei She, PhD, Sarah Crouch, BA (Hons), William Rees, PhD, May Mo, MS, and René van der Merwe, MBChB*

---

**Dermatopathology**

- 1022** Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study  
**Bottom line:** Nonsuperficial treatment failures were less frequently observed after imiquimod therapy than after treatment with methylaminolevulinate-photodynamic therapy or 5-fluorouracil and were more often located in the head and neck area. Close follow-up is necessary.  
*Lieke C. J. van Delft, MD, Patty J. Nelemans, MD, PhD, Maud H. E. Jansen, MD, Aimee H. M. M. Arits, MD, PhD, Marieke H. Roozeboom, MD, PhD, Myrurgia A. Hamid, MD, PhD, Klara Mosterd, MD, PhD, and Nicole W. J. Kelleners-Smeets, MD, PhD*

**From the Academy**

 **1029**

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

*Alan Menter, MD (Co-Chair), Bruce E. Strober, MD, PhD, Daniel H. Kaplan, MD, PhD, Dario Kivelevitch, MD, Elizabeth Farley Prater, MD, Benjamin Stoff, MD, MA, April W. Armstrong, MD, MPH, Cody Connor, MD, Kelly M. Cordoro, MD, Dawn M. R. Davis, MD, Boni E. Elewski, MD, Joel M. Gelfand, MD, MSCE, Kenneth B. Gordon, MD, Alice B. Gottlieb, MD, PhD, Arthur Kavanaugh, MD, Matthew Kiselica, Neil J. Korman, MD, PhD, Daniela Krushinsky, MD, MPH, Mark Lebwohl, MD, Craig L. Leonardi, MD, Jason Lichten, MD, Henry W. Lim, MD, Nehal N. Mehta, MD, MSCE, Amy S. Paller, MD, Sylvia L. Parra, MD, Arun L. Pathy, MD, Reena N. Rupani, MD, Michael Siegel, PhD, Emily B. Wong, MD, Jashin J. Wu, MD, Vidhya Hariharan, PhD, and Craig A. Elmets, MD (Co-Chair)*

**1073**

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

*Craig A. Elmets, MD (Co-Chair), Craig L. Leonardi, MD, Dawn M. R. Davis, MD, Joel M. Gelfand, MD, MSCE, Jason Lichten, MD, Nehal N. Mehta, MD, MSCE, April W. Armstrong, MD, MPH, Cody Connor, MD, Kelly M. Cordoro, MD, Boni E. Elewski, MD, Kenneth B. Gordon, MD, Alice B. Gottlieb, MD, PhD, Daniel H. Kaplan, MD, PhD, Arthur Kavanaugh, MD, Dario Kivelevitch, MD, Matthew Kiselica, Neil J. Korman, MD, PhD, Daniela Krushinsky, MD, MPH, Mark Lebwohl, MD, Henry W. Lim, MD, Amy S. Paller, MD, Sylvia L. Parra, MD, Arun L. Pathy, MD, Elizabeth Farley Prater, MD, Reena Rupani, MD, Michael Siegel, PhD, Benjamin Stoff, MD, MA, Bruce E. Strober, MD, PhD, Emily B. Wong, MD, Jashin J. Wu, MD, Vidhya Hariharan, PhD, and Alan Menter, MD (Co-Chair)*

**Reviews**

**1114**

Emerging imaging technologies in dermatology

Part I: Basic principles

**Bottom line: New emerging technologies include confocal microscopy, optical coherence tomography, high-frequency ultrasound, Raman spectroscopy, and fluorescence imaging, which may be integrated into clinical practice to aid in patient diagnosis and management.**

*Samantha L. Schneider, MD, Indermeet Kohli, PhD, Iltefat H. Hamzavi, MD, M. Laurin Council, MD, Anthony M. Rossi, MD, and David M. Ozog, MD*

**1121**

Emerging imaging technologies in dermatology

Part II: Applications and limitations

**Bottom line: With improving technology and usability, imaging devices will become important tools for clinicians.**

*Samantha L. Schneider, MD, Indermeet Kohli, PhD, Iltefat H. Hamzavi, MD, M. Laurin Council, MD, Anthony M. Rossi, MD, and David M. Ozog, MD*

**Research Letters**

**1132**

Parameters in fractional laser assisted delivery of topical anesthetics: A randomized controlled study on the role of the anesthetic and application time

*Arne A. Meesters, MD, Marilyn J. Nieboer, MD, Menno A. de Rie, MD, PhD, and Albert Wolkerstorfer, MD, PhD*

- 1133** Predominance of oral mucosal melanoma in areas of high mechanical stress  
*Pooja H. Rambhia, BA, Ivan J. Stojanov, DMD, and Joshua Arbesman, MD*
- 1135** Trends in utilization of topical medications for treatment of rosacea in the United States (2005-2014): A cohort analysis  
*Hadar Lev-Tov, MD, MAS, Joanne S. Rill, MD, Guodong Liu, PhD, MS, and Joslyn S. Kirby, MD, MS, MEd*
- 1137** The associations of depression and coping methods on health-related quality of life for those with hidradenitis suppurativa  
*Melissa Butt, MPH, Mia Sisic, MA, Colleen Silva, MD, Haley B. Naik, MD, MHSc, Solveig Esmann, MA, Gregor Jemec, MD, DMSc, and Joslyn S. Kirby, MD, MS, MEd*
- 1139** Deficiency of sun protection advertising exists in consumer magazines across demographic groups and varies by target demographic  
*Lauren E. Wiznia, MD, Jenny Wang, MD, Alexa B. Steuer, MPH, and Nada Elbuluk, MD, MSc*
- 1141** Tumor necrosis factor- $\alpha$  inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study  
*Laurie Rousset, MD, Adèle de Masson, MD, PhD, Edouard Begon, MD, Axel Villani, MD, Maxime Battistella, MD, PhD, Michel Rybojad, MD, Marie Jachiet, MD, Martine Bagot, MD, PhD, Jean-David Bouaziz, MD, PhD, and Clémence Lepelletier, MD*
- 1143** Recent dermatology visit is associated with thinner Breslow depth nodular melanomas  
*Erin X. Wei, MD, Lucy Chen, MD, Fangchao Ma, PhD, Jonette Keri, MD, PhD, and Shasa Hu, MD*
- 1144** Effect of postinjection facial exercise on time of onset of botulinum toxin for glabella and forehead wrinkles: A randomized, controlled, crossover clinical trial  
*Murad Alam, MD, MSCI, MBA, Amelia Geisler, BS, Melanie Warycha, MD, Kapila Paghдал, MD, Wanjarus Roongpisuthipong, MD, Daniel I. Schlessinger, BA, Brian R. Chen, MD, Kelly A. Reynolds, BA, Dennis P. West, PhD, and Emily Poon, PhD*
- 1147** Lack of evidence for feminization of males exposed to spironolactone in utero: A systematic review  
*Walter Liszewski, MD, and Christina Boull, MD*
- 1148** High-throughput sequencing of the T-cell receptor  $\beta$  chain gene distinguishes 2 subgroups of cutaneous T-cell lymphoma  
*Jie Wang, MD, Bryan Rea, MD, Paul Haun, MD, Ryan Emerson, PhD, Ilan Kirsch, MD, and Adam Bagg, MD*

- 1150** Histologic predictors of invasion in partially biopsied lentigo maligna melanoma  
*Iman Aouidad, MD, Céline Fargeas, MD, Pierre Romero, MD, Jean-François Sei, MD, Véronique Chaussade, MD, Alain Beauchet, MD, Thierry Clerici, MD, Ute Zimmermann, MD, Philippe Saiag, MD, PhD, and Elisa Funck-Brentano, MD, PhD*
- 1152** Noncultured epidermal suspension grafting using suction blisters as donor tissue for vitiligo  
*Andrea Tovar-Garza, MD, Jorge A. Hinojosa, MD, Linda S. Hynan, PhD, and Amit G. Pandya, MD*
- 1154** Merkel cell carcinoma incidence, trends, and survival rates among adults aged  $\geq 50$  years from United States Cancer Statistics  
*MaryBeth B. Freeman, MPH, Dawn M. Holman, MPH, Jin Qin, ScD, and Natasha Buchanan Lunsford, PhD*
- 1157** Trends in incidence of cutaneous malignant melanoma in Canada: 1992-2010 versus 2011-2015  
*Feras M. Ghazawi, MD, PhD, Michelle Le, BSc, Nebras Alghazawi, BSc, Elham Rahme, PhD, Linda Moreau, MD, FRCPC, Elena Netchiporouk, MD, FRCPC, Andrei Zubarev, MSc, Osama Roshdy, MD, Steven J. Glassman, MD, Denis Sasseville, MD, FRCPC, and Ivan V. Litvinov, MD, PhD, FRCPC*
- 1159** Abnormal erythrocyte morphology in drug reaction with eosinophilia and systemic symptoms  
*Deborah N. Dorrell, BA, Litton F. Whitaker, BS, Kathryn L. Anderson, MD, and Lindsay C. Strowd, MD*
- 1160** Initiation of methotrexate with or without a test dose: A retrospective toxicity study  
*Thomas Herrmann, BS, Michael Buhnerkempe, PhD, and Morgan L. Wilson, DVM, MD*
- 1162** Evaluating results of an interferon- $\gamma$  release assay in patients with autoimmune disease who are taking hydroxychloroquine  
*Rebecca G. Gaffney, BA, and Victoria P. Werth, MD*
- 1164** Tofacitinib therapy for children with severe alopecia areata  
*Ying-Xiu Dai, MD, and Chih-Chiang Chen, MD, PhD*
- 1166** A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis  
*Naina Chipalkatti, BS, Nicole Lee, BA, Pedro Zancanaro, MD, Nicole Dumont, Courtney Kachuk, RN, and David Rosmarin, MD*

**Health Policy & Practice**

- 1168** Time to reconsider the role of sentinel lymph node biopsy in melanoma  
*Michael Bigby, MD, Samuel Zagarella, MD, Michael Sladden, MD, and Catalin M. Popescu, MD*

**Dermatoethics Consultation**

- 1172** Just a quick pic: Ethics of medical photography  
*Tiana Kazemi, BA, Kachiu C. Lee, MD, MPH, and Lionel Bercovitch, MD*

---

<b>Beyond JAAD</b>	<b>1175</b>	Beyond JAAD April 2019: Articles of interest to dermatologists from the nondermatologic literature <i>Andrew Bronin, MD, Robert Phelps, MD, and Robert Sidbury, MD</i>
--------------------	-------------	---

---

**JAAD ONLINE** Available at <http://www.jaad.org>

<b>Clinical Pearl</b>	<b>e69</b>	An effective, low-cost technique for photograph and video capture, wireless transmission, and quality assurance assessments for dermatopathology, anatomic pathology, and Mohs micrographic surgery <i>Jonathan Kantor, MD, MSCE, MA</i>
<b>Therapeutic Pearls</b>	<b>e71</b>	Clobetasol pretreatment to reduce and prevent injection site dermatitis from biologic agents <i>Deede Liu, MD, Dominic J. Wu, MD, Anand Rajpara, MD, Ting Wang, MD, and Daniel J. Aires, MD, JD</i>
	<b>e73</b>	Treatment of purpura with Nd:YAG laser in skin types IV-VI <i>Dana S. Saade, MD, and Neelam A. Vashi, MD</i>
	<b>e75</b>	5-Fluorouracil as an adjuvant therapy along with microneedling in vitiligo <i>Abhijeet Kumar Jha, MD, and Sidharth Sonthalia, MD, DNB, MNAMS</i>
<b>Surgical Pearl</b>	<b>e77</b>	2-to-Z flap for reconstruction of adjacent skin defects <i>Collin M. Blattner, DO, Benjamin Perry, DO, John Young, MD, and William Lear, MD</i>
<b>Notes &amp; Comments</b>	<b>e79</b>	Comment on “Surgical smoke: Risk assessment and mitigation strategies” and chemical adsorption by activated carbon N95 masks <i>Carlos Gustavo Wambier, MD, PhD, Kachiu Cecilia Lee, MD, MPH, Patrícia Botini de Oliveira, MD, Sarah Perillo de Farias Wambier, MD, PhD, and Flávio Luís Beltrame, PharmD, PhD</i>
	<b>e81</b>	Reply to: “Comment on ‘Surgical smoke: Risk assessment and mitigation strategies’ and chemical adsorption by activated carbon N95 masks” <i>Corey Georgesen, MD, and Shari R. Lipner, MD, PhD</i>
	<b>e83</b>	Comment on “Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up” <i>Noureddine Litaïem, MD, Asma Toumi, MD, and Faten Zeglaoui, MD, PhD</i>
	<b>e85</b>	Reply to: “Comment on ‘Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up’” <i>Laura Miguel-Gómez, MD, PhD, David Saceda-Corralo, MD, PhD, and Sergio Vañó-Galván, MD, PhD</i>

---

	<b>e87</b>	New validated diagnostic criteria for pyoderma gangrenosum <i>Emanuel Maverakis, MD, Stephanie T. Le, MD, Jeffrey Callen, MD, Uwe Wollina, MD, Angelo Valerio Marzano, MD, Daniel Wallach, MD, Courtney Schadt, MD, Yocasta C. Martinez-Alvarado, MD, Michelle Y. Cheng, MD, Chelsea Ma, MD, Alexander Merleev, PhD, Anthony Ormerod, MD, Fiona Craig, MRCP, Finja Jockenhofer, MD, Joachim Dissemond, MD, Katrin Salva, MD, Hywel C. Williams, DSc, and David Fiorentino, MD, PhD</i>
	<b>e89</b>	Reply to: “New validated diagnostic criteria for pyoderma gangrenosum” <i>Hovik J. Ashchyan, MD, Caroline A. Nelson, MD, Sasha Stephen, MD, William D. James, MD, Robert G. Micheletti, MD, and Misha Rosenbach, MD</i>
	<b>e91</b>	Ex vivo confocal microscopy of basal cell carcinoma on a 3-color scale <i>Mercedes Sendín-Martín, MD, Antoni Bennàssar, MD, PhD, Konstantin L. Levitsky, PhD, and Javier J. Domínguez-Cruz, MD, PhD</i>
<b>In Memoriam</b>	<b>e93</b>	Thomas P. Habif, MD <i>James G. Dinulos, MD, Richard D. Baughman, MD, and Paulette Dinulos, MPH</i>
<b>Book Review</b>	<b>e95</b>	Facial reconstruction after Mohs surgery, 1st edition <i>Brian C. Leach, MD</i>
<b>Iotaderma</b>	<b>e97</b>	Iotaderma (#302) <i>Robert I. Rudolph, MD, FACP</i>

---

<b>JAAD Game Changers</b>	<b>882</b>	JAAD Game Changers: Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD) <i>Eden Lake, MD</i>
	<b>900</b>	JAAD Game Changers: Standardized laboratory monitoring with use of isotretinoin in acne <i>Eden Lake, MD</i>
	<b>1178</b>	JAAD Game Changers: Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study <i>Eden Lake, MD</i>

To access the current version of the Information for Authors, Transfer of Copyright Form, Authorship Declaration Form, Conflict of Interest Disclosure, and Authors' Rights Statement, as well as many other pertinent documents, please visit our website at [www.jaad.org/content/auth\\_page](http://www.jaad.org/content/auth_page).

Full text access to *Journal of the American Academy of Dermatology Online* is now available for Academy members and all print subscribers. To activate your online subscription, please visit *Journal of the American Academy of Dermatology Online* by pointing your browser to <http://www.jaad.org>.

---

**Icon Key**

	=	<b>CME article</b>
	=	<b>Video content available at <a href="http://www.jaad.org">http://www.jaad.org</a></b>
	=	<b>Podcast available at <a href="http://www.aad.org/olc">http://www.aad.org/olc</a></b>
	=	<b>MOC credits available</b>

**Early online publication: Articles in press**

The *Journal of the American Academy of Dermatology* posts in-press articles online before they appear in the print edition of the *Journal*. These Articles in Press are available from both the JAAD website ([www.jaad.org](http://www.jaad.org)) and Science Direct ([www.sciencedirect.com](http://www.sciencedirect.com)). To access Articles in Press, simply click the Articles in Press link.

**JAAD Case Reports**

The *Journal of the American Academy of Dermatology* no longer publishes Case Reports. These can now be found in our new open access journal, *JAAD Case Reports*, at <http://www.jaadcasereports.org>.